R-1234 Roscovitine, Free Base, >99% [CYC202] [Seliciclib] [6-Benzylamino-2[(R)-(1′-ethyl-2′-hydroxyethylamino)]-9-isopropylpurine] M.W. 354.45 C19H26N6O [186692-46-6] M.I. 14: 10240 Storage: Store at or below -20 ºC. Solubility: Prepare initial stock solutions in DMSO (soluble at 200 mg/mL) or ethanol (soluble at 200 mg/mL) for in vitro use; solubility in water is low. Appearance: White to off-white powder. Disposal: A •Roscovitine is a potent inhibitor of p34cdc2 (IC50 = 0.2 µM). Also inhibits p33cdk2 and p33cdk5. Havlicek, L., et al. “Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.” J. Med. Chem. 40: 408-412 (1997). •NOTE: The word “Roscovitine” inherently means the R-isomer. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses.
